U.S. market Closed. Opens in 10 hours 12 minutes

PROK | ProKidney Corp. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 4.35 - 4.98
52 Week Range 3.95 - 14.19
Beta 1.58
Implied Volatility 280.00%
IV Rank 78.42%
Day's Volume 658,707
Average Volume 320,760
Shares Outstanding 419,404,029
Market Cap 1,975,392,977
Sector Healthcare
Industry Biotechnology
IPO Date 2021-06-30
P/E Ratio -8.72
Forward P/E Ratio N/A
EPS -0.54
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 87
Country USA
Website PROK
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
*Chart delayed
Analyzing fundamentals for PROK we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see PROK Fundamentals page.

Watching at PROK technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PROK Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙